Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis
- 1 January 2018
- journal article
- review article
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 22 (1) , 52-64
Abstract
Amyotrophic lateral sclerosis (ALS) is a rare but usually fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and the spinal cord. Two forms are recognized, the familial that accounts for 5–10% and the sporadic that accounts for the rest. New studies suggest that ALS is a highly heterogeneous disease, and this diversity is a major reason for the lack of successful therapeutic treatments. Indeed, only two drugs (riluzole and edaravone) have been approved that provide a limited improvement in the quality of life. Presently, the diagnosis of ALS is based on clinical examination and lag period from the onset of symptoms to the final diagnosis is ∼12 months. Therefore, the discovery of robust molecular biomarkers that can assist in the diagnosis is of major importance. DNA sequencing to identify pathogenic gene variants can be applied in the cases of familial ALS. However, it is not a routinely used diagnostic procedure and most importantly, it cannot be applied in the diagnosis of sporadic ALS. In this expert review, the current approaches in identification of new ALS biomarkers are discussed. The advent of various multi-omics biotechnology platforms, including miRNomics, proteomics, metabolomics, metallomics, volatolomics, and viromics, has assisted in the identification of new biomarkers. The biofluids are the most preferable material for the analysis of potential biomarkers (such as proteins and cell-free miRNAs), since they are easily obtained. In the near future, the biofluid-based biomarkers will be indispensable to classify different ALS subtypes and understand the molecular heterogeneity of the disease.Keywords
This publication has 103 references indexed in Scilit:
- Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in bloodActa Neuropathologica, 2013
- Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated seleniteNeuroToxicology, 2013
- Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published LiteratureNeuroepidemiology, 2013
- A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosisGene, 2012
- TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexesProceedings of the National Academy of Sciences, 2012
- Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosisAnnals of Neurology, 2010
- MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in MiceScience, 2009
- Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathiesActa Neuropathologica, 2009
- The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementiaCurrent Opinion in Neurology, 2008
- Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutationsAnnals of Neurology, 2007